Antonios Papanicolau-Sengos, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 3S235B
- Bethesda, MD 20892
- 240-858-3489
- antonios.papanicolau-sengos@nih.gov
RESEARCH SUMMARY
Dr. Papanicolau-Sengos left CCR in December 2023. He is a molecular pathologist. He is interested in targeted oncotherapeutics, the molecular classification of neoplasms, and machine learning applications in molecular pathology
Areas of Expertise
Antonios Papanicolau-Sengos, M.D.
Research
I am interested in new analytical technologies in the context of molecular pathology. An example is the application of machine learning techniques on large-scale DNA methylation studies. The combination of these technologies has already proved excellent in helping neuropathologists classify central nervous system (CNS) neoplasms. Another interest of mine is the molecular characterization of rare familial neoplasms which are not currently well-represented in medical literature.
Publications
- Bibliography Link
- View Dr. Papanicolau-Sengos' PubMed Summary.
Identification of targets for prostate cancer immunotherapy
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
Biography
Antonios Papanicolau-Sengos, M.D.
Dr. Papanicolau-Sengos received his medical degree from Georgetown School of Medicine and has completed a pathology residency (AP/CP) at the University of California San Diego, a general surgical pathology fellowship at the University of Washington, and a molecular pathology fellowship at ARUP laboratories. Previously, Dr. Papanicolau-Sengos has held positions at the molecular pathology laboratory of Roswell Park Comprehensive Cancer Center and its spin-off company OmniSeq Inc.